[A17-05] Ceritinib (lung cancer) - Addendum to Commission A16-62
Last updated 16.03.2017
Project no.:
A17-05
Commission:
Commission awarded on 06.02.2017 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A16-62 | Ceritinib (lung cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2017-03-16 A G-BA decision was published.